Durvalumab and radiation for extensive-stage small cell lung cancer that has spread to a few spots
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving radiation therapy after a good response to durvalumab plus chemotherapy can help keep extensive-stage small cell lung cancer from growing for as long as possible. If you qualify, you would receive radiation to the tumor areas in your chest and any remaining spots where the cancer had spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have small cell lung cancer that has spread to a limited number of places (fewer than 5 total).
- You must have completed 4-6 cycles of durvalumab (an immunotherapy) with standard chemotherapy, and your cancer must have shrunk or disappeared after that treatment.
- You must be between 18 and 70 years old.
- You must be in generally good health (able to do daily activities without major help).
- Your liver, kidneys, and blood counts must be within normal limits.
- You must not have had a heart attack, stroke, or uncontrolled high blood pressure in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of durvalumab (immunotherapy) plus radiation and chemotherapy for people with extensive-stage small cell lung cancer that has only a few distant spots. The goal is to see if this approach helps control the cancer better.
This Phase 2 study tests durvalumab (an immunotherapy) together with focused, ablative radiation to treat metastatic small cell lung cancer. It may help shrink tumors and improve outcomes, especially when at least one tumor can be safely targeted with this radiation plan.
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
This study tests whether adding radiation therapy to the chest after initial chemotherapy and immunotherapy can help keep extensive stage small cell lung cancer under control longer. It is designed for people whose cancer responded well to the first round of treatment.
This Phase 2 trial tests whether adding monalizumab to durvalumab (two immune-targeting medicines) can improve outcomes in people with small cell lung cancer. You may be able to join if you have certain stage of small cell lung cancer and have not had the specific prior treatments the study allows.
This trial tests whether the immunotherapy drug durvalumab can help keep limited-stage small cell lung cancer from coming back after standard treatment. You would receive durvalumab as a 'consolidation' (maintenance) therapy.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.